BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.

@article{Derr2010BTLAMI,
  title={BTLA mediates inhibition of human tumor-specific CD8+ T cells that can be partially reversed by vaccination.},
  author={Laurent Derr{\'e} and Jean-Paul Rivals and Camilla Jandus and Sonia Pastor and Donata Rimoldi and Pedro Romero and Olivier Michielin and Daniel Olive and Daniel E Speiser},
  journal={The Journal of clinical investigation},
  year={2010},
  volume={120 1},
  pages={157-67}
}
The function of antigen-specific CD8+ T cells, which may protect against both infectious and malignant diseases, can be impaired by ligation of their inhibitory receptors, which include CTL-associated protein 4 (CTLA-4) and programmed cell death 1 (PD-1). Recently, B and T lymphocyte attenuator (BTLA) was identified as a novel inhibitory receptor with structural and functional similarities to CTLA-4 and PD-1. BTLA triggering leads to decreased antimicrobial and autoimmune T cell responses in… CONTINUE READING